Author(s):
Alvina Arum Puspitasari, Zullies Ikawati, Sri Swasthikawati, Anindya Rahmawati
Email(s):
zullies_ikawati@ugm.ac.id , ikawati@yahoo.com
DOI:
10.52711/0974-360X.2022.00133 
Address:
Alvina Arum Puspitasari1, Zullies Ikawati2*, Sri Swasthikawati3, Anindya Rahmawati1
1Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
2Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
3Research Centre for Biotechnology, Indonesian Institute of Science, Bogor, Indonesia.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2022
ABSTRACT:
Opioid receptor mu-1 (OPRM1) A118G gene polymorphism has been widely studied as a strong candidate gene for increasing risk of drug addiction. However, the association is still controversial concerning the effect of A118G polymorphisms on drug addiction seems to be different inter-ethnic. The prevalence of OPRM1 A118G polymorphism is found to be low in the European American population but high in the Asian population. To date, there are very limited reports on this polymorphism in the Indonesian population and its association with drug addiction. Here, we carry out the genotyping of OPRM1 A118G polymorphism in Indonesian population using amplification refractory mutation system polymerase chain reaction (ARMS-PCR) method. The result shows that the OPRM1 A118G polymorphism is relatively higher compared with other Asian countries. When comparing the frequency of the genotype and allele between the normal (n = 83) and the drug-addicted (n = 83) subjects, no significant difference in prevalence was found in neither genotype (p = 0.066, 95% CI [confidence interval]) nor allele (p = 0.432; 95% CI) between the groups. Our results suggest that there is no direct effect of OPRM1 A118G gene polymorphism on the risk of drug addiction (including stimulants, marijuana, and benzodiazepine) among Indonesian; instead, social factors might play a key role.
Cite this article:
Alvina Arum Puspitasari, Zullies Ikawati, Sri Swasthikawati, Anindya Rahmawati. Genotyping of Opioid Receptor Mu 1 (OPRM1) A118G Polymorphism in Indonesian Drug Addicts. Research Journal of Pharmacy and Technology. 2022; 15(2):799-6. doi: 10.52711/0974-360X.2022.00133
Cite(Electronic):
Alvina Arum Puspitasari, Zullies Ikawati, Sri Swasthikawati, Anindya Rahmawati. Genotyping of Opioid Receptor Mu 1 (OPRM1) A118G Polymorphism in Indonesian Drug Addicts. Research Journal of Pharmacy and Technology. 2022; 15(2):799-6. doi: 10.52711/0974-360X.2022.00133 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-2-53
REFERENCES:
1. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Substance-Related and Addictive Disorders. Arlington, VA, The American Psychiatric Association (APA). 2013.
2. Sharma M, Nagori K, Agrawal S, Verma VS, Swarnakar H, Vaishnav S, Nazir M, Khan N, Singh A. Drug Abuse: A Curse for Human Society. Asian J. Res. Pharm. Sci. 2014; 4(2): 99-109
3. Dogra SK, Bagga R. Drug Addiction vis-a-vis Defense of Insanity in India: A Comparative Study. Res. J. Humanities and Social Sciences. 2019; 10(2): 559-567
4. Duaux E, Krebs MO, Loo H, Poirier MF. Genetic Vulnerability to Drug Abuse. European Psychiatry. 2020; 15(2): 109-114
5. Hart A, de-Wit H, Palmer A. Genetic Factors Modulating the Response to Stimulant Drugs in Humans. Curr Top Behav Neurosci. 2012; 12: 537–577
6. Clarke T, Crist R, Kampman K, Dackis C, Pettinati H, O’Brien C, Oslinb D, Ferraroa TN, Lohoff FW, Berrettini WH. Low frequency genetic variants in the µ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. Neuroscience Letters. 2013; 542: 71– 75
7. Hasan A, Azawi IH, Al-Hilali HA. Cysteine leukotriene receptors type 2 (CyLTR2 M01 V) gene polymorphism and its role in Iraqi asthmatic patients. Research J. Pharm. and Tech. 2019; 12(9): 4125-4128
8. Gaidan AM, Abbas AA, Hassan MA, Hashim HM, Al-Mayah QS. The Impact of IL-10 C-597A Gene Polymorphisms on Asthma Susceptibility. Research J. Pharm. and Tech. 2017; 10(9): 2867-2870
9. Patel SK, Sinha M, Mitra M. Glutathione-S-transferase M1 and T1 gene Polymorphism as Risk Factors of Oral Squamous Cell Carcinoma: A Preliminary Investigation. Research J. Pharm. and Tech. 2012; 5(7): 918-920
10. Thakre TR, Singh A, Mitra M. Investigation on Glutathione-S-transferase M1 and T1 gene polymorphisms as risk factor in Cervical Cancer. Research J. Pharm. and Tech. 2016; 9(12): 2295-2300
11. Thakre TR, Singh A, Mitra M. Association of TNF-308 gene polymorphism with Cervix Cancer susceptibility among women of Chhattisgarh. Research J. Pharm. and Tech. 2019; 12(5): 2339-2342
12. Surhan RK, Darweesh M, Al-Obiadi AB. IL-10-1082A\G gene polymorphism and production in β-thalassemia major and association with HCV infection. Research J. Pharm. and Tech. 2018; 11(6): 2603-2608
13. Maddhuri S, Vemuri PK, Tatineni J, Puppala J. Association of Calcineurin B (PPP3R1) Functional Gene Polymorphism in South Indian Children with Idiopathic Mental Retardation. Research J. Pharm. and Tech 2020; 13(2): 599-603
14. Crist R, Reiner B, and Berrettini WH. A Review of Opioid Addiction Genetics. Current Opinion in Psychology. 2019; 27: 31–35
15. Hancock DB, Levy J, Gaddis N, Glasheen C, Saccone N, Page G, Hulse GK, Wildenauer D, Kelty EA, Schwab SG, et al. Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. Biological Psychiatry. 2015; 78: 474–484
16. Schwantes-An T, Zhang J, Chen L, Hartz S, Culverhouse R, Chen X, Coon H, Frank J, Kamens HM, Konte B, et al. Association of the OPRM1 variant rs1799971 (A118G) with non-specific liability to substance dependence in a collaborative de novo meta-analysis of European-ancestry cohorts. Behavior genetis. 2016; 46: 151–169
17. Dlugos AM, Hamidovic A, Hodgkinson C, Shen PH, Goldman D, Palmer AA and de Wit H. OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes Brain Behav. 2011; 10(2): 199–209
18. Woodcock EA, Lundah LH, Burmeister M, and Greenwald MK. Functional Mu Opioid Receptor Polymorphism (OPRM1 A118G) Associated With Heroin Use Outcomes in Caucasian Males: A Pilot Study. Am J Addict. 2015; 24(4): 329–335
19. Kumar D, Chakraborty J, and Das S. Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2012; 36: 225–230
20. Nikolov M, Beltcheva O, Galabova A, Ljubenova A, Jankova E, Gergov G, Russev AA, Lynskey MT, Nelson EC, Nesheva E, et al. `No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case control sample. Drug Alcohol Depend. 2011; 117(1): 62–65
21. National Narcotic Board (NNB). Survei Prevalensi Penyalahgunaan Narkoba Tahun 2019. National Narcotic Board of Republic Indonesia, published by the Center of Research, Data, and Information. 2020; pp. 121-122
22. Zahari Z, Siong LC, Yeh LY, Ibrahim MA, Musa N, Yasin MD, Choon TS, Mohammad N, Ismail R. 118A>G And IVS2+691G>C Polymorphisms of OPRM1 Gene have No Influence on Cold-Pain Sensitivity among Healthy Opioid-Naive Malay Males. Int J Pharm Pharm Sci. 2016; 8: 73-80
23. Rodriguez S, Gaunt T, and Day I. Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies. Am J Epidemiol. 2009; 169(4): 505-14
24. Windle M, Gray JC, Lei KM, Barton AW, Brody G, Beach SR, Galván A, MacKillop J, Clark US, Sweet LH. Age sensitive associations of adolescent substance use with amygdala, ventral striatum, and frontal volumes in young adulthood. Drug and Alcohol Dependence. 2018; 186: 94-101
25. Koechl B, Ungera A, and Fischer G. Age-related aspects of addiction. Gerontology. 2012; 58(6): 540–544
26. Smith TW, Hout M, and Marsden PV. General Social Survey, 1972-2012 [Cumulative File]. ICPSR34802-v1. Storrs, CT: Roper Center for Public Opinion Research, University of Connecticut /Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributors]. 2013.
27. Fothergill KE, Ensminger ME, Green KM, Crum RM, Robertson J, Juon HS. The impact of early school behavior and educational achievement on adult drug use disorders: a prospective study. Drug and alcohol dependence. 2008; 92(1-3): 191–199
28. Badel A, Greaney B. Exploring the Link between Drug Use and Job Status in the U.S. St. Louis Fed.: The Regional Economist. 2013.
29. Zahari Z, Ibrahim MA, Musa N, Tan SC, Mohamad N, Ismail R. Sleep quality and OPRM1 polymorphisms: a cross-sectional study among opioid-naive individuals. Braz. J. Pharm. Sci. 2018; 54(1): e17217
30. Puspitasari AA, Ikawati Z, Swasthikawati S, and Rahmawati A. High Frequency of the Opioid Receptor μ-1 (OPRM1) A118G Polymorphism, an Opioid Drug Therapy Related Gene, in the Indonesian Population. Current Pharmacogenomics and Personalized Medicine. 2019; 17: 1-6
31. Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, et. al. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y AcadSci. 2004; 1025: 316–24
32. Tan EC, Tan CH, Karupathivan U, and Yap EP. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport. 2003; 14(4): 569-572
33. Ahmed M, UlHaq I, Faisal M, Waseem D, Taqi MM. Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis. Journal of molecular neuroscience. 2018; 65(4): 472–479
34. Türkan H, Karahalil B, Kadıoğlu E, Eren K, Gürol DT, and Karakaya AE. The association between the OPRM1 A118G polymorphism and addiction in a Turkish population. ArhHig Rada Toksikol. 2019; 70: 97-103
35. Hofer T, Ray N, Wegmann D, Excoffier L. Large Allele Frequency Differences between Human Continental Groups are more likely to have Occurred by Drift During range Expansions than by Selection. Annals of Human Genetics. 2009; 73: 95-108
36. Mattei J, Parnel LD, Lai C, Bailo B, Adiconis X, Shen J, Arnett D, Demissie S, Tucker KL, and Ordovas JM. Disparities in allele frequencies and population differentiation for 101 disease-associated single nucleotide polymorphisms between Puerto Ricans and non-Hispanic whites. BMC Genetics. 2009; 10: 45
37. Lewis CM. Genetic association studies: Design, analysis and interpretation. Briefings in Bioinformatics. 2002; 3(2): 146–153
38. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci. 1998; 95(16): 9608–9613
39. Tien LT and Ho IK. Involvement of µ-Opioid Receptor in Methamphetamine-Induced Behavioral Sensitization. CurrNeuropharmacol. 2011; 9(1): 215–218
40. Olson KM, Lei W, Keresztes A, LaVigne J, and Streichera JM. Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain. Yale J Biol Med. 2017; 90(1): 97–110
41. Singh AK. Alcohol Interaction with Cocaine, Methamphetamine, Opioids, Nicotine, Cannabis, and γ-Hydroxybutyric Acid. Biomedicines. 2019; 7(16).
42. Stafford AM, Reed C, Philips TJ. Taar1 gene variants have a causal role in methamphetamine intake and response and interact with Oprm1. eLife. 2019; 8: e46472
43. Arias A, Feinn R, Kranzler HR. Association of an Asn40asp (A118G) Polymorphism in the Mu-Opioid Receptor Gene with Substance Dependence: A Meta-Analysis. Drug Alcohol Depend. 2006; 83: 262–268
44. Hwang IC, Park JY, Myung SK, Ahn HY, Fukuda K, and Liao Q. OPRM1 A118G Gene Variant and Postoperative Opioid Requirement: A Systematic Review and Meta-analysis. Anesthesiology. 2014; 121: 825–834
45. Nagaya D, Ramanathan S, Ravichandran M, Navaratnam V. A118G mu opioid receptor polymorphism among drug addicts in Malaysia. J Integr Neurosci. 2012; 11(1): 117-122
46. Kelly JF, Stout RL, Greene MC, Slaymaker V. Young Adults, Social Networks, and Addiction Recovery: Post Treatment Changes in Social Ties and Their Role as a Mediator of 12-Step Participation. PLoS ONE. 2014; 9(6): e100121
47. Aghaii S, Kamaly A, Esfahani M. Meta-Analysis of Individual and Environmental Factors that Influence People’s Addiction Tendencies. Int J High Risk Behav Addict. 2012; 1(3): 92-99
48. Nair B, Mathew J, Mathew A. Nomophobia – A Rising Pathology of Non-Drug Addiction. Int. J. Nur. Edu. and Research. 2019; 7(4): 620-624
49. Kumar P, Pokotylyuk I, Kulshrestha S, and Loewy Z. Clinical Relevance of µ-Opioid Receptor A118G Polymorphism in Demographically Variant Populations. EC Pharmacology and Toxicology. 2018; 6(4): 228-236